Literature DB >> 31593481

Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis.

Mi Na Kim1, Beom Kyung Kim2, Seung Up Kim2, Jun Yong Park2, Sang Hoon Ahn2, Kwang-Hyub Han2, Do Young Kim2.   

Abstract

Background/aims: Cirrhosis is an important risk factor for hepatocellular carcinoma (HCC), and the surveillance of patients with cirrhosis is, therefore, highly recommended. However, the role of alpha-fetoprotein (AFP) in HCC surveillance is controversial. The aim of this study was to determine the role of AFP in HCC surveillance among patients with cirrhosis.
Methods: The study population consisted of 392 patients with cirrhosis. Ultrasound (US) and laboratory tests including AFP were regularly performed to detect HCC development. The cutoff level of AFP for suspicion of HCC was 7 ng/mL.
Results: During the median follow-up period of 4.7 (interquartile range, 3.4-5.6) years, HCC developed in 64 (16.3%) patients. Their mean age was 53.6 years, and they were predominantly male (63.5%). For the detection of HCCs, the sensitivity and specificity of US were 56.3% and 100%, respectively. The sensitivity and specificity of AFP were 62.5% and 94.5%, respectively. Using US and AFP in combination increased the sensitivity of surveillance to 89.1% with a specificity of 94.5%. Mean AFP levels were significantly higher in patients with than without HCC at the time of HCC diagnosis, at 6 months and 12 months before the diagnosis. The area under the receiver operating characteristic curve of AFP was highest at the time of HCC diagnosis (0.867), and also was acceptable at 6 months (0.823) and 12 months (0.792) before the diagnosis.Conclusions: These results suggest the complementary use of AFP and US to improve the effectiveness of HCC surveillance in patients with cirrhosis.

Entities:  

Keywords:  HCC; alpha-fetoprotein; cirrhosis; surveillance; ultrasound

Year:  2019        PMID: 31593481     DOI: 10.1080/00365521.2019.1673478

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Dong Ho Lee; Ijin Joo; Ju Hyun Jeon; Su Joa Ahn; Seung-Taek Kim; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  Liver Cancer       Date:  2020-08-06       Impact factor: 11.740

2.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

3.  PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.

Authors:  Honglei Feng; Bole Li; Ze Li; Qian Wei; Li Ren
Journal:  BMC Cancer       Date:  2021-04-13       Impact factor: 4.430

4.  Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection.

Authors:  Fei Ye; Wei Huang; Yuan Xue; Xinxin Zhang; Erjiang Tang; Mingjie Wang; Fengchun Shi; Dong Wei; Yue Han; Peizhan Chen; Demin Yu
Journal:  J Hepatocell Carcinoma       Date:  2021-04-27

5.  A high preoperative serum IL-25 level is a negative prognosis predictor after liver resection for HBV-HCC.

Authors:  Shao-Hua Chen; Xu Wang
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

6.  Construction and validation of a predictive model for hepatocellular carcinoma based on serum markers.

Authors:  Liming Zheng; Zeyu Huang; Xiaoping Li; Meifang He; Xiaoqin Liu; Guojun Zheng; Xike Zhou; Longgen Liu
Journal:  BMC Gastroenterol       Date:  2022-09-13       Impact factor: 2.847

7.  Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis.

Authors:  Amit G Singal; Benjamin Haaland; Neehar D Parikh; A Burak Ozbay; Carol Kirshner; Shubham Chakankar; Kyle Porter; Jagpreet Chhatwal; Turgay Ayer
Journal:  Hepatol Commun       Date:  2022-08-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.